NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, 2025 – Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI Cancer Spectrum validating Read More
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® in Diverse Patient Populations Across Breast Cancer Subtypes IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 27, 2025 – Agendia®, Inc., a leader in precision Read More
Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting
FLEX Study reaches milestone of 20,000 enrolled patients, providing new insights on genomic testing across diverse patient populations IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 15, 2025 – Agendia®, Inc., announced today that Read More
Newsroom
News, Stories & Breast Cancer Blog
Mapping Your Path: How Genomic Testing Can Personalize Your Breast Cancer Treatment Plan
Genomic testing can help personalize your breast cancer treatment plan by helping map a path ahead. When navigating a breast cancer diagnosis, it can feel like approaching one fork in the road after another. Read More
Test May Predict Breast Cancer Recurrence Risk, Chemotherapy Benefit
For patients with HR+, HER2- early breast cancer, MammaPrint may predict distant recurrence-free interval prognosis and chemotherapy benefit.Key TakeawaysMammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer.High-risk patients benefit significantly Read More
Understanding Predictive vs. Prognostic Breast Cancer Genomic Testing
What Does Your Breast Cancer Genomic Test Really Tell You— and Why MammaPrint’s Latest Data Matters? If you or someone you love has been diagnosed with early-stage breast cancer, especially HR-positive/ HER2-negative breast cancer, you've likely Read More
Genetic vs. Genomic Testing in Early-Stage Breast Cancer: What You Need to Know?
How these tests can help create a treatment plan that’s right for you Navigating Your Diagnosis Being diagnosed with early-stage breast cancer can feel overwhelming. You’re asked to make important decisions—often quickly—while trying to Read More
Agendia Named 2025 “Best Overall Genomics Company” By MedTech Breakthrough
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital Read More
The Endocrine System and Breast Cancer Overview
The endocrine system is a series of glands responsible for creating and distributing hormones throughout the body, chemical messengers of sorts. This important system plays a role in many bodily functions, including regulating metabolism, Read More
Disparities in Breast Cancer Care, Genomic Insights and Early Detection
By Ryan Scott | March 19, 2025 Black women face a 40% higher mortality rate from breast cancer compared with other groups, according to the Breast Cancer Research Foundation, highlighting a disparity in detection, Read More
